Moreover, combining GPX4 inhibitors with anti-PD1 has been found to effectively induce ferroptosis in triple-negative breast cancer, demonstrating superior therapeutic efficacy compared with monotherapy.41 This evidence concerns the gene GPX4 and triple-negative breast carcinoma.